{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:07:52Z","timestamp":1767838072033,"version":"3.49.0"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol Surg B Skull Base"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Introduction\u2003Cushing's disease (CD) is associated with hypercoagulability which is associated with an increased risk of venous thromboembolic events (VTEs) perioperatively. This risk persists even after successful transsphenoidal surgery (TSS). However, there are no current guidelines for pharmacologic thromboprophylaxis in this patient population.<\/jats:p><jats:p>\n          Objective\u2003Characterize existing thromboprophylaxis management practices in patients undergoing TSS for CD.<\/jats:p><jats:p>\n          Methods\u2003An anonymous RedCap survey comprised of questions about perioperative thromboprophylaxis in CD patients was distributed via the American Association of Neurological Surgeons (AANS)\/Congress of Neurological Surgeons (CNS) Joint Tumor Section and the North American Skull Base Society (NASBS) email lists.<\/jats:p><jats:p>\n          Results\u2003The survey was distributed to 554 members of the AANS\/CNS Joint Tumor Section and 1,094 members of NASBS asking that members who surgically treat CD respond. Sixty responses (3.0% response rate) were received. Fifty-two (86.7%) respondents are involved in the postoperative management of CD patients. Thirty-six (69.2%) treat all patients with postoperative VTE chemoprophylaxis, 8 (15.4%) treat some patients, while 8 (15.4%) do not use chemoprophylaxis. Preferred chemoprophylaxis varies as 26 (59.1%) administer low molecular weight heparin, 14 (31.8%) give unfractionated heparin, 1 (2.3%) give direct oral anticoagulants, and 3 (6.8%) give aspirin. Most (28, 53.8%) of the respondents perceive the VTE risk in this patient population to be 0 to 5%, 16 (30.8%) perceive the risk to be 6 to 10%, and 8 (15.4%) perceive it to be 11 to 20%.<\/jats:p><jats:p>\n          Conclusion\u2003There is great variability in VTE detection and postoperative prevention practice patterns in CD patients. This study highlights the need for prospective studies to clarify optimal pharmacologic chemoprophylaxis strategies and duration in this patient population.<\/jats:p>","DOI":"10.1055\/s-0043-1772698","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T23:34:30Z","timestamp":1693352070000},"page":"540-545","source":"Crossref","is-referenced-by-count":2,"title":["Significant Variability in Postoperative Thromboprophylaxis in Cushing's Disease Patients: A Survey of the North American Skull Base Society and the AANS\/CNS Joint Tumor Section"],"prefix":"10.1055","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4704-6578","authenticated-orcid":false,"given":"Alexandra J.","family":"White","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, United States"},{"name":"Section of Skull Base Surgery, Rose Ella Burkhardt Brain Tumor & Neuro-oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, United States"},{"name":"Department of Neurosurgery, Mayo Clinic, Jacksonville, Florida, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Paulo","family":"Almeida","sequence":"additional","affiliation":[{"name":"Section of Skull Base Surgery, Rose Ella Burkhardt Brain Tumor & Neuro-oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, United States"},{"name":"Department of Neurosurgery, Mayo Clinic, Jacksonville, Florida, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan C.","family":"Petitt","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Yogi-Morren","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes & Metabolism, Cleveland Clinic Foundation, Cleveland, Ohio, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9748-2784","authenticated-orcid":false,"given":"Pablo F.","family":"Recinos","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, United States"},{"name":"Section of Skull Base Surgery, Rose Ella Burkhardt Brain Tumor & Neuro-oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3217-8279","authenticated-orcid":false,"given":"Varun R.","family":"Kshettry","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, United States"},{"name":"Section of Skull Base Surgery, Rose Ella Burkhardt Brain Tumor & Neuro-oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/EJE-15-0308","article-title":"Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect","volume":"173","author":"A M Isidori","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.wneu.2019.10.077","article-title":"Cerebral venous sinus thrombosis after transsphenoidal resection: a rare complication of Cushing disease-associated hypercoagulability","volume":"134","author":"P Soni","year":"2020","journal-title":"World Neurosurg"},{"issue":"08","key":"ref3","first-page":"3662","article-title":"Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome","volume":"87","author":"M Boscaro","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3389\/fendo.2018.00805","article-title":"Hypercoagulability and risk of venous thromboembolic events in endogenous Cushing's syndrome: a systematic meta-analysis","volume":"9","author":"J Wagner","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2265.2012.04479.x","article-title":"Hypercoagulable state in Cushing's syndrome is reversible following remission","volume":"78","author":"D Kastelan","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF03345709","article-title":"Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels","volume":"32","author":"C Erem","year":"2009","journal-title":"J Endocrinol Invest"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.wneu.2022.03.076","article-title":"MRI-negative Cushing's disease: a review on therapeutic management","volume":"162","author":"M Sabahi","year":"2022","journal-title":"World Neurosurg"},{"issue":"S 25","key":"ref8","first-page":"S640","article-title":"Surgical management of recurrent Cushing's disease in pregnancy: a case report","volume":"6","author":"M Abbassy","year":"2015","journal-title":"Surg Neurol Int"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF03401535","article-title":"Pathogenesis of vascular complications in Cushing's syndrome","volume":"11","author":"P Miljic","year":"2012","journal-title":"Hormones (Athens)"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11102-014-0600-y","article-title":"Perioperative thromboprophylaxis in Cushing's disease: what we did and what we are doing?","volume":"18","author":"M Barbot","year":"2015","journal-title":"Pituitary"},{"issue":"09","key":"ref11","doi-asserted-by":"crossref","first-page":"101371","DOI":"10.1016\/j.inat.2021.101371","article-title":"Venous thromboembolic (VTE) prophylaxis in Cushing disease patients undergoing transsphenoidal surgery","volume":"27","author":"J P McCormick","year":"2022","journal-title":"Interdiscip Neurosurg"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"M Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"D A Garcia","year":"2012","journal-title":"Chest"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejim.2021.03.030","article-title":"Weight-adjusted versus fixed dose heparin thromboprophylaxis in hospitalized obese patients: a systematic review and meta-analysis","volume":"88","author":"D Ceccato","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.otc.2021.12.016","article-title":"Pituitary gland surgical emergencies: the role of endoscopic intervention","volume":"55","author":"M A Arnold","year":"2022","journal-title":"Otolaryngol Clin North Am"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1002\/hed.27179","article-title":"Endoscopic pituitary surgery: national database review","volume":"44","author":"Z Al-Qurayshi","year":"2022","journal-title":"Head Neck"},{"issue":"05","key":"ref17","first-page":"1","article-title":"Complications associated with microscopic and endoscopic transsphenoidal pituitary surgery: experience of 1153 consecutive cases treated at a single tertiary care pituitary center","volume":"130","author":"M S Agam","year":"2018","journal-title":"J Neurosurg"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/02688697.2022.2047888","article-title":"Post-operative vision loss: analysis of 587 patients undergoing endoscopic surgery for pituitary macroadenoma","volume":"36","author":"J W Rutland","year":"2022","journal-title":"Br J Neurosurg"},{"issue":"03","key":"ref19","first-page":"1","article-title":"Incidence and risk factors associated with reoperation for sellar hematoma following endoscopic transsphenoidal pituitary surgery","volume":"133","author":"I Younus","year":"2019","journal-title":"J Neurosurg"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11102-021-01195-8","article-title":"Venous thromboembolism chemical prophylaxis after endoscopic trans-sphenoidal pituitary surgery","volume":"25","author":"M Waqar","year":"2022","journal-title":"Pituitary"},{"issue":"S 05","key":"ref21","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Q T Ostrom","year":"2019","journal-title":"Neuro-oncol"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"A F Daly","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1210\/jc.2003-030461","article-title":"Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume","volume":"88","author":"F G Barker II","year":"2003","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Neurological Surgery Part B: Skull Base"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1772698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:22:24Z","timestamp":1730805744000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1772698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":23,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2024,9,2]]},"published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1772698","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2193-6331","2193-634X"],"issn-type":[{"value":"2193-6331","type":"print"},{"value":"2193-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]}}}